ESR1 and obesity due to melanocortin 4 receptor deficiency: Hormone replacement therapy (HRT, primarily estrogen) and selective estrogen receptor modulators (SERMs) improve metabolic disorders, including obesity, type 2 diabetes, dyslipidemia, and osteoarthritis, by activating estrogen receptor-related pathways [9, 10].